In this article, we will take a look at the 13 Best Strong Buy Dividend Stocks to Invest In.
In uncertain times, large companies that pay strong dividends tend to attract more attention, as these businesses generate profits supported by steady cash flows, which help sustain dividend payments even during moderate economic slowdowns. That consistency matters, and it reflects financial strength and careful management. Companies that commit to maintaining or increasing dividends must stay disciplined. They cannot afford to invest recklessly. Every capital decision has to support both growth and shareholder returns. This kind of discipline often leads to stronger balance sheets and more stable long-term performance.
These fundamentals help explain why dividend strategies can perform relatively well in both rising and volatile markets, although this is not assured. According to a report by VanEck, 2025 illustrated this clearly. The VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF proved less volatile than global markets, represented by the MSCI World Index, after the US announced tariffs in April 2025. The report stated:
“As 2025 shows, they can provide resilience in volatile markets. Our research indicates that dividends have underpinned stock returns over the past 80 years, especially when inflation has spiked higher as it did in the 1940s and 1970s.”
This reflects how income from dividends can help support returns even when broader market conditions become more difficult. As investors refocus on fundamentals, dividends are once again gaining attention. Stock price gains often dominate headlines, but dividends have quietly played a major role in total returns. Over time, this income becomes a meaningful contributor to overall performance.
In addition, over the past 35 years, reinvested dividends have accounted for roughly half of the total return generated by the S&P 500. This is significant as it shows that long-term gains did not come only from rising stock prices, but also from the steady income companies returned to shareholders and the compounding effect of reinvesting those payments.
Given this, we will take a look at some of the best Strong Buy dividend stocks to invest in.
Our Methodology:
For this list, we screened for dividend stocks with positive analyst sentiment and identified stocks with consensus Strong Buy ratings. These companies are also popular among hedge funds. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
13. The Cigna Group (NYSE:CI)
On February 17, Truist raised its price recommendation on The Cigna Group (NYSE:CI) to $350 from $320. The firm reiterated a Buy rating on the stock. The analyst updated the firm’s model following the company’s Q4 results and its initial outlook for 2026, pointing to improved visibility into the business trajectory.
David Cordani, the company’s CEO and Chair, said The Cigna Group delivered adjusted revenue of $275 billion for the full year, marking an 11% increase. He also noted that adjusted earnings per share came in at $29.84, up 9% compared with the previous year, reflecting steady underlying growth.
He added that the company continued to reposition its portfolio through a series of strategic moves. These included increasing its investment in Shields Health Solutions and completing the divestiture of Cigna Healthcare’s Medicare business. Cordani also said the company had resolved its Federal Trade Commission matters through a broad settlement tied to its pharmacy benefits operations. He stated that the agreement is expected to deliver “$7 billion in out-of-pocket cost relief over the next 10 years for the 100 million customers and patients we serve.”
Cordani also pointed to the launch of a rebate-free pharmacy benefit model. The initiative was first developed in early 2025 and formally introduced in the third quarter. He said the model “enhances the value we provide to customers and clients, all while we continue to strengthen our position and deliver on our long-term shareholder commitments.”
The Cigna Group operates as a global health company, with its business anchored around two main growth platforms: Evernorth Health Services and Cigna Healthcare.
12. West Pharmaceutical Services, Inc. (NYSE:WST)
On February 13, BofA lowered its price recommendation on West Pharmaceutical Services, Inc. (NYSE:WST) to $300 from $370. It reiterated a Buy rating on the stock. The firm’s view followed what it described as “a solid finish to the year,” along with FY26 guidance that came in ahead of expectations. The outlook reflected accelerating growth in its non-GLP-1 high-value products segment. After reviewing the company’s earnings and updated guidance, BofA revised its financial model. The firm also applied a lower valuation multiple, pointing to broader group compression across the sector.
A few days later, on February 16, 2026, West Pharmaceutical Services announced that its Board of Directors had declared a regular quarterly dividend of $0.22 per share on its common stock. The dividend will be paid on May 6, 2026, to shareholders on record as of April 29, 2026. This move continued the company’s established pattern of returning capital to shareholders.
On February 17, 2026, the Board took another step in that direction by authorizing a new share repurchase program. The plan allows the company to buy back up to $1 billion of its common stock, reinforcing its commitment to shareholder returns and capital allocation discipline.
West Pharmaceutical Services, Inc. (NYSE:WST) remains a key player in the healthcare supply chain. The company provides specialized solutions that support injectable drug delivery. By working closely with both established pharmaceutical firms and emerging biotech developers, West plays an important role in helping ensure that critical medicines are safely contained and delivered to patients.
